Published in Ther Clin Risk Manag on April 01, 2008
Biologics in dermatologic therapy - an update. Indian J Dermatol (2009) 0.82
Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature. Clin Cosmet Investig Dermatol (2010) 0.75
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 3.92
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.51
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) 1.77
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol (2002) 1.68
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol (2006) 1.58
Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis (2005) 1.56
Treatment of psoriasis with adalimumab. Clin Exp Dermatol (2007) 1.48
Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol (1998) 1.39
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes (2006) 1.31
Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis (2002) 1.13
Infliximab for psoriasis. J Am Acad Dermatol (2003) 0.97
Molecular differences in anticytokine therapies. Clin Exp Rheumatol (2003) 0.97
The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res (2006) 0.90
Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol (2004) 0.85
Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking J Invest Dermatol (2000) 0.83
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis (2012) 2.29
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol (2005) 2.28
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) 1.77
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol (2008) 1.54
Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol (2002) 1.54
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48
The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol (2008) 1.45
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol (2003) 1.16
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol (2004) 1.15
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol (2010) 1.10
Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol (2005) 1.07
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol (2007) 1.03
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg (2010) 0.99
Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc (2006) 0.92
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. Blood (2002) 0.91
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol (2006) 0.91
Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg (2002) 0.90
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol (2006) 0.89
The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol (2003) 0.88
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat (2007) 0.88
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol (2010) 0.88
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther (2009) 0.86
Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol (2003) 0.84
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol (2012) 0.82
Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol (2013) 0.81
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol (2006) 0.81
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol (2013) 0.79
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther (2005) 0.79
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci (2007) 0.78
Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther (2004) 0.78
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat (2007) 0.78
Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf (2002) 0.78
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb) (2012) 0.77
From laboratory to clinic: rationale for biologic therapy. Dermatol Clin (2004) 0.77
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol (2010) 0.76
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb) (2012) 0.76
Patient education and advocacy groups: a means to better outcomes? Arch Dermatol (2005) 0.76
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid (2010) 0.75
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg (2005) 0.75
Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol (2010) 0.75
Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol (2007) 0.75
The new psoriasis pathway: toward a unified theory of immunopathogenesis. Expert Rev Clin Immunol (2007) 0.75